WHAT IS CP101?

THE investigational DRUG BEING STUDIED IN PRISM 3 is cp101

The study drug (CP101, a Full-Spectrum Microbiota™ product) is an investigational drug designed to deliver a broad range of bacteria to your intestine. This study will help determine if this broad range of bacteria can prevent the recurrence of C. difficile infection (CDI). CP101 is considered "investigational" because it has not been approved by the US Food and Drug Administration for preventing recurrence of C. diff infection. 

ORALLY-ADMINISTERED

CP101 is in a pill that trial participants will take by mouth. The pills are designed to release bacteria in the right part of your gut.

A FULL-SPECTRUM MICROBIOTA™ (FSM™) PRODUCT

CP101 is our FSM™ product, meaning it is designed to deliver a broad range of bacteria that are found in the human gut. CP101 was developed from scientific evidence that has shown a diverse range of bacteria have an important role in maintaining and restoring gut health.